$0.78
1.40% today
Nasdaq, Feb 28, 04:23 pm CET
ISIN
US65343E1082
Symbol
NXTC
Sector
Industry

NextCure, Inc. Stock price

$0.77
-0.04 5.35% 1M
-0.81 51.33% 6M
-0.00 0.26% YTD
-0.80 50.86% 1Y
-4.13 84.31% 3Y
-40.25 98.13% 5Y
-14.23 94.87% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.01 1.72%
ISIN
US65343E1082
Symbol
NXTC
Sector
Industry

Key metrics

Market capitalization $21.54m
Enterprise Value $-48.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.07
P/B ratio (TTM) P/B ratio 0.28
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-60.54m
Free Cash Flow (TTM) Free Cash Flow $-45.03m
Cash position $75.31m
EPS (TTM) EPS $-2.09
P/E forward negative
Short interest 0.21%
Show more

Is NextCure, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

NextCure, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a NextCure, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a NextCure, Inc. forecast:

Buy
100%

Financial data from NextCure, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.17 3.17
30% 30%
-
-3.17 -3.17
30% 30%
-
- Selling and Administrative Expenses 9.80 9.80
16% 16%
-
- Research and Development Expense 44 44
9% 9%
-
-57 -57
12% 12%
-
- Depreciation and Amortization 3.17 3.17
30% 30%
-
EBIT (Operating Income) EBIT -61 -61
13% 13%
-
Net Profit -59 -59
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about NextCure, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NextCure, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multi...
Neutral
GlobeNewsWire
3 months ago
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences
Neutral
GlobeNewsWire
3 months ago
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00...
More NextCure, Inc. News

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Head office United States
CEO Michael Richman
Employees 82
Founded 2015
Website www.nextcure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today